A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.
Adam Sharp(Institute of Cancer Research), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Sarah Whelan(Nurix (United States)), Anja Williams(Sarah Cannon Research Institute), Elizabeth Ruth Plummer, T.R. Jeffry Evans(Leiden University Medical Center), Sarah P. Blagden(Churchill Hospital), Johann S. de Bono(Royal Marsden NHS Foundation Trust), K. Jameson, Matthew Krebs(Christie's), Daniel Hochhauser(Royal London Hospital), Frank G. Basile(Nurix (United States)), Srinand Nandakumar(Nurix (United States)), Seema Rogers(Nurix (United States)), Simon Pacey(Royal Marsden NHS Foundation Trust)
Cited by 12
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k